Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular accumulation of amyloid deposits and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau proteins. Brainderived neurotrophic factor (BDNF) is a neurotrophic factor playing a critical role in hippocampal synaptic plasticity and memory and whose levels have been shown reduced in AD brains. While recent data support a pivotal role of β-amyloid peptides towards BDNF decrease, whether Tau pathology impacts on BDNF expression remains unknown so far. In the present study, we have evaluated this relationship using quantitative PCR, Western blot and ELISA in the THY-Tau22 transgenic strain, known to display a progressive development of both hippocampal AD-like Tau pathology and memory impairments. We observed that Tau pathology was not associated with down-regulation of BDNF at the protein and mRNA levels in this model, suggesting that the alteration of BDNF homeostasis observed in AD patients’ brains might rather be ascribed to amyloid pathology.
Keywords: Alzheimer’s disease, BDNF, neurotrophins, tau, tauopathies, transgenic models, Protein Expression, ELISA analysis, synaptic plasticity, homeostasis
Current Alzheimer Research
Title:Hippocampal BDNF Expression in a Tau Transgenic Mouse Model
Volume: 9 Issue: 4
Author(s): Sylvie Burnouf, Karim Belarbi, Laetitia Troquier, Maxime Derisbourg, Dominique Demeyer, Antoine Leboucher and Cyril Laurent, Malika Hamdane, Luc Buee, David Blum
Affiliation:
Keywords: Alzheimer’s disease, BDNF, neurotrophins, tau, tauopathies, transgenic models, Protein Expression, ELISA analysis, synaptic plasticity, homeostasis
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular accumulation of amyloid deposits and intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated Tau proteins. Brainderived neurotrophic factor (BDNF) is a neurotrophic factor playing a critical role in hippocampal synaptic plasticity and memory and whose levels have been shown reduced in AD brains. While recent data support a pivotal role of β-amyloid peptides towards BDNF decrease, whether Tau pathology impacts on BDNF expression remains unknown so far. In the present study, we have evaluated this relationship using quantitative PCR, Western blot and ELISA in the THY-Tau22 transgenic strain, known to display a progressive development of both hippocampal AD-like Tau pathology and memory impairments. We observed that Tau pathology was not associated with down-regulation of BDNF at the protein and mRNA levels in this model, suggesting that the alteration of BDNF homeostasis observed in AD patients’ brains might rather be ascribed to amyloid pathology.
Export Options
About this article
Cite this article as:
Sylvie Burnouf, Karim Belarbi, Laetitia Troquier, Maxime Derisbourg, Dominique Demeyer, Antoine Leboucher and Cyril Laurent, Malika Hamdane, Luc Buee, David Blum , Hippocampal BDNF Expression in a Tau Transgenic Mouse Model, Current Alzheimer Research 2012; 9 (4) . https://dx.doi.org/10.2174/156720512800492468
DOI https://dx.doi.org/10.2174/156720512800492468 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Morphine as a Potential Oxidative Stress-Causing Agent
Mini-Reviews in Organic Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Delineating Characteristic Sequence and Structural Features of Precursor and Mature Piwi-interacting RNAs of Epithelial Ovarian Cancer
Current Bioinformatics Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Mangiferin – a Bioactive Xanthonoid, not only from Mango and not just Antioxidant
Mini-Reviews in Medicinal Chemistry 4-Substituted-2-Methoxyphenol: Suitable Building Block to Prepare New Bioactive Natural-like Hydroxylated Biphenyls
Letters in Drug Design & Discovery Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review
Current Neuropharmacology mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Inhibition of Early Biochemical Defects in Prodromal Huntington’s disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients
Current Aging Science